When patients ask whether inflammatory bowel disease (IBD) "runs in families," the answer depends on which condition they're discussing. For Crohn's disease and ulcerative colitis (UC), genetics plays a substantial role. For microscopic colitis (MC), genetics appears to be more of a contributing factor than a primary driver although the full story may be more complex than current research suggests. A strong genetic signal exists in Crohn's and UC: Crohn's disease and UC show clear genetic influence. Researchers have identified over 200 genetic risk variants associated with these conditions, with several carrying particularly strong effects.
The evidence is robust. First-degree relatives of IBD patients face a 5–10 fold increased risk compared to the general population. Twin studies reveal that if one identical twin develops Crohn's disease, the other has approximately a 50% chance of developing it as well. Yet this 50% probably rate also reveals genetics' limitations. Despite sharing identical DNA, half of the co-twins remain disease-free, demonstrating that environmental factors play essential roles even in genetically driven diseases. The weaker, but authentic, genetic component in MC: MC shows a distinctly different genetic profile. While familial clustering occurs, it's far less pronounced than in Crohn's or UC. No dominant gene comparable to NOD2 has been found. Instead, MC shows modest associations with immune-related genes, particularly in the HLA (human leukocyte antigen) system. The most notable associations involve HLA-DQ2 and HLA-DQ8 — the same variants strongly linked to celiac disease. These genes don't "cause" MC directly, but determine how the immune system recognizes and responds to foreign proteins from food, bacteria, and medications. This genetic architecture, shared with celiac disease, raises an intriguing possibility — MC may present not so much as a unique disease, but more as a symptom of gluten sensitivity in individuals carrying these HLA variants. People with HLA-DQ2 or HLA-DQ8 show altered immune responses to gluten and other dietary antigens, which could explain why MC patients typically improve with dietary modifications despite testing negative for celiac disease. The genetic contribution to MC appears substantially weaker than in Crohn's or UC. Many MC patients report no family history of the condition, and many people carrying identified risk genes never develop MC. This pattern suggests genetics primarily establishes susceptibility (lowering the risk threshold for inflammation), while environmental factors exert greater influence on whether the disease actually develops. How genetic susceptibility works: Genetic risk variants don't directly cause disease. Instead, they modify biological processes that influence vulnerability to disease. Genes like HLA-DQ2 and HLA-DQ8 determine which proteins the immune system flags as threats versus harmless substances. Variants reducing tolerance to dietary proteins or gut bacteria increase inflammatory responses to everyday exposures. Other genetic variants affecting tight junction proteins or mucus production may create a more permeable intestinal barrier, allowing greater antigen exposure and immune activation. Genes controlling cytokine production and inflammatory signaling pathways influence how aggressively the immune system reacts to triggers. Some variants generate exaggerated responses to modest provocations. Additionally, genetic factors affecting tissue repair and immune resolution may slow healing after inflammatory episodes, prolonging symptoms and increasing the risk of developing a chronic condition. Think of genetics as a way to adjust an inflammatory thermostat. With susceptible genes, the inflammatory "temperature" rises more easily, stays elevated longer, and requires less provocation to spike. Environmental triggers are where MC diverges from the other IBDs The relatively weak genetic signal in MC becomes more significant when considering the condition's strong environmental associations. Unlike Crohn's disease, where genetics can drive disease even with modest environmental triggers, MC typically requires substantial environmental provocation. Common MC triggers include:
Many MC patients can identify a clear event that likely triggered their disease, such as starting a new medication, recovering from food poisoning, or completing an antibiotic course. This pattern contrasts sharply with Crohn's disease, where onset often appears more spontaneous, and less tied to specific exposures. The medication associations are particularly worth noting. Studies suggest that 20–40% of MC cases involve recent medication use, with NSAIDs and PPIs as frequent culprits. This environmental dominance explains why MC treatment often succeeds through trigger removal — stopping offending medications, or eliminating problem foods, rather than requiring the aggressive immune system suppression typical of Crohn's or UC treatments. But an important question is evident when treatment protocols are compared. Does this difference reflect true biological distinctions between MC and the other IBDs, or does it simply reveal biased treatment approaches? The medical community didn't discover that avoiding certain medications and making dietary changes could resolve MC symptoms — MC patients discovered this themselves, after being frustrated by gastroenterologists' limited understanding of the disease, and experiencing disappointing treatment results. And notably, some Crohn's and UC patients have found that avoiding these same medications, and implementing similar dietary changes, can put their disease in remission without the powerful drugs typically prescribed to treat Crohns disease and UC. This suggests the supposed environmental differences between MC and the other IBDs may be overstated, or at least that triggers associated with environmental factors deserves much more serious consideration in Crohn's and UC management than it currently receives. Perhaps the contrast exists not because Crohn's and UC lack environmental triggers, but because conventional medical treatment protocols have never seriously explored the effectiveness of modifications to address environmental factors as a primary therapeutic approach for these conditions. Gene-Environment interactions — looking at the bigger picture: The most accurate disease model for MC and the other IBDs involves gene-environment interactions, though the balance differs between conditions. In Crohn's disease and UC, genetics provides substantial disease risk, with environmental factors modulating expression, severity, and timing. A person carrying high-risk NOD2 variants faces considerable IBD risk even with typical environmental exposures. In MC, genetics establishes susceptibility (although a lower inflammatory threshold), but environmental triggers appear to drive actual disease development. A person with HLA-DQ2 might remain healthy until exposed to chronic NSAID use, severe gastrointestinal infection, or prolonged PPI therapy. However, if environmental modification proves effective for some Crohn's and UC patients, the gene-environment balance in these conditions may be more similar to MC than currently recognized. The apparent differences might reflect treatment philosophy (aka bias) rather than fundamental disease biology. Please note that this is currently speculation — just my opinion. But if medical researchers ever decide to perform a properly-designed study to investigate these factors to either confirm, or rule them out, there's a very good chance they will discover that environmental triggers are indeed a major issue for most Crohn's and UC patients, and they should be incorporated into treatment programs. Perhaps the optimal treatment of Crohn's and UC is as misunderstood as the treatment for MC, and the drugs typically prescribed as treatments just manage to work sufficiently well that both gastroenterologists and patients perceive them as adequate, despite the risky side effects. But sadly, medical treatments for Crohn's and UC leave a lot to be desired. According to statistics:
For MC patients, the statistics show the risk of intestinal resection to be less than 1%. Practical implications: Understanding the role of genetics in MC and other IBDs is necessary for practical clinical results:
The bottom line: Genetics matters in both “classic” IBDs and MC, but its role differs fundamentally — or it at least appears to differ, based on current treatment approaches.
In Crohn's disease and UC, genetic factors exert strong influence, though environmental factors remain important. In MC, genetics establishes susceptibility while environmental triggers appear to drive disease development and progression. For MC patients, this offers genuine hope. Unlike conditions where genetics seems to determine destiny, MC's environmental dominance means identifying and eliminating triggers often achieves lasting remission. Our genes may establish susceptibility, but they don't make disease inevitable. The environmental factors we control, including medication choices, dietary modifications, and microbiome health, often matter more than genetic factors (that we can't change). Yet the discovery that environmental modification helps some Crohn's and UC patients suggests the distinction between these conditions and MC may be less absolute than conventional wisdom holds. Perhaps genetics loads the gun in all these conditions, but environment pulls the trigger, and in all cases, unloading environmental triggers deserves more attention than it typically receives in gastroenterology practice. This understanding shifts focus from fatalistic acceptance of genetic risk, toward proactive management of controllable factors. For conditions where conventional medicine often provides limited guidance, recognizing that environment frequently trumps genetics empowers patients to pursue meaningful interventions toward achieving and maintaining remission.
0 Comments
The Pursuit of Longevity Has Influenced Many Internet Influencers to Became a Public Health Problem10/18/2026
There's a new category of health authority that didn't exist a generation ago. They appear on YouTube, TikTok, Instagram, Substack, and podcasts. They cite scientific papers, wear continuous glucose monitors, document their supplement stacks in spreadsheet-style graphics, and speak in fluent biomedical vocabulary. Some have large physician followings. A few hold medical degrees themselves. Collectively, they have built a multi-trillion-dollar marketplace around a central promise — aging, disease, and physical decline can be optimized, reversed, or indefinitely delayed with the right combination of products, protocols, and information, most of which they happen to sell or can be purchased though an affiliate-link. This is not a fringe phenomenon. According to the Pew Research Center 40% of U.S. adults report getting health and wellness information from social media influencers or podcasts (Stocking, et al., 2026, May 7).1 The wellness industry, powered substantially by influencer-driven promotion, was valued at $6.8 trillion in 2024 (Global Wellness Institute, 2025).2 The regulatory gap that makes this possible: The entire structure of the influencer wellness economy rests on a regulatory loophole that most consumers don't realize exists. Prescription medications require pre-market proof of safety and efficacy through rigorous clinical trials before they can become available to patients. Dietary supplements in the United States operate under an entirely different framework. Under the Dietary Supplement Health and Education Act of 1994, manufacturers are not required to demonstrate safety or effectiveness before selling their products. The FDA can intervene only after harm has been documented in the marketplace — which means consumers function as a de facto post-market surveillance system (U.S. Food & Drug Administration. (n.d.).3 The practical consequences of this framework are not theoretical. A 2023 review in Livers found that herbal and dietary supplements generate over 50,000 adverse events annually in the United States, and a prospective study tracking drug-induced liver injury found that supplements accounted for 16% of cases overall, with that proportion rising from 7% in 2004–05 to 20% in 2013–14 (Lin, and Tujios, 2023).4 A 2024 Lancet Gastroenterology & Hepatology analysis estimated that 5% of American adults had used at least one of six potentially hepatotoxic supplements in the past 30 days, extrapolating to approximately 15 million people (The Lancet Gastroenterology & Hepatology, 2024).5 Turmeric and ashwagandha — both enthusiastically promoted by wellness influencers — now appear prominently in liver injury case reports and systematic reviews (Björnsson, et al., 2020).6 This is a situation in which consumers are not protected by the FDA, platform oversight, or any other regulatory oversight. They're on their own. And in case anyone is wondering — yes, European countries highly regulate the sale of dietary supplements, which are classified and regulated as food products. The industry is governed by strict, coordinated European Union laws, with additional country-specific requirements. Supplement stacking — when does more become dangerous? One of the signature behaviors promoted by wellness influencers is "supplement stacking" — the practice of taking multiple supplements simultaneously to optimize different physiological pathways at once. A given protocol might include a NAD+ precursor, omega-3 fatty acids, ashwagandha, magnesium, resveratrol, coenzyme Q10, creatine, vitamin D, vitamin K2, zinc, berberine, and several other compounds, all taken in a single day's regimen. NAD+ (Nicotinamide Adenine Dinucleotide) precursors are compounds that the body converts into NAD+, an essential coenzyme required for cellular energy production, DNA repair, and sirtuin activation. Natural NAD+ levels are claimed by influencers to decline significantly with age, and therefore, taking precursors supposedly counters age-related metabolic and cellular decline. The fundamental problem is that combining multiple bioactive compounds generates interaction effects and cumulative effects that no one has studied, (and no one is ever likely to study). The human data on individual supplements are already limited; the data on combinations don't exist at all. What does exist is a well-documented clinical principle — the probability of adverse interactions increases nonlinearly as the number of concurrent substances increases. Several categories of risk are particularly relevant.
That last point is specifically relevant to older adults, who are the primary demographic at risk for osteoporosis, metabolic disease, and the other conditions that influencers most aggressively target. Younger people typically have a broader tolerance range than older people. Older adults typically have reduced kidney function, multiple prescription medications, and comorbidities that alter the pharmacokinetics of every substance they consume. A stack designed for a healthy 32-year-old does not carry the same risk profile in a 68-year-old with hypertension and reduced kidney function. But influencers rarely make this distinction, and their followers rarely think to ask. The peptide problem: One of the most medically concerning developments associated with influencers involves injectable peptides now marketed openly on TikTok, YouTube, and wellness forums as anti-aging, regenerative, and performance-enhancing therapies. Compounds including BPC-157, TB-500, and CJC-1295 are presented to consumers as cutting-edge regenerative medicine, available online at low cost. BPC-157 illustrates the problem clearly. It's a synthetic fifteen-amino-acid peptide derived from a protein found in human gastric juice, studied primarily in laboratory animals. It has not been approved for human use by any drug regulatory agency worldwide. No completed clinical trials have established either its safety or effectiveness in humans — a single registered trial under the name Bepecin in 2015 did not result in any approved medical use. The FDA has confirmed there is no legal basis for compounding pharmacies to include BPC-157 in medications, and no legal basis for selling it as a drug or dietary supplement. The World Anti-Doping Agency banned it in 2022 under its S0 category — "Non-Approved Substances" — which covers any pharmacological substance not approved by a recognized government authority for human therapeutic use. The U.S. Department of Defense has placed it on its Prohibited Dietary Supplement Ingredients List for the same reasons. Despite all of this, BPC-157 is widely sold online, typically labeled as a "research chemical", which is a classification used specifically to sidestep regulatory oversight. The practical consequences of that gray market are predictable — independent analysis has identified mislabeling, improper dosing, or contamination in approximately 30% of peptide samples from gray-market sources. Because BPC-157 promotes angiogenesis (the formation of new blood vessels) theoretical concerns exist about potential cancer-promoting effects that remain uninvestigated in humans. Consumers injecting these compounds have no way to verify purity, confirm concentration, or anticipate systemic effects that no adequate human safety data exists to predict. The influencers promoting these compounds rarely mention any of the risks. The animal study translation problem: A consistent pattern across longevity marketing is the presentation of animal study findings to consumers as though they constitute evidence of human benefit. This translation problem is not unique to the wellness influencer industry — it occurs in pharmaceutical development too — but it's more systematically exploited by influencers, because there's no regulatory requirement to correct it. NAD+ precursor supplements, primarily nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN), offer the clearest current example — and a newly published study makes the problem considerably worse for the supplement industry than previously understood. These compounds became commercially prominent after rodent studies suggested they could raise tissue NAD+ levels, improve metabolic function, and extend healthspan. The entire marketing plan rests on a single basic claim; namely, that aging causes NAD+ levels to decline, creating a deficit that supplementation can restore. That premise has now been directly contradicted by a rigorously designed human study published in Nature Metabolism in May 2026. Using validated ultra-high-performance liquid chromatography with high-resolution mass spectrometry across seven independent human cohorts, researchers at Amsterdam UMC found that whole-blood NAD+ levels remain remarkably stable across age groups and are unaffected by lifestyle interventions. NR supplementation did raise blood NAD+ concentrations, confirming that the measurement method was functioning correctly — but the age-related NAD+ decline that underpins the entire supplementation rationale was not observed. The authors concluded that blood NAD+ levels are not a valid biomarker of aging (Trętowicz et al., 2026).7 This does not answer every question about NAD+ biology, and the issue of whether tissue-level dynamics differ from whole-blood measurements remains an open area of investigation. But it directly invalidates the basic foundation of the marketing claim. Consumers spending $50 to $100 per month on NMN or NR are paying to restore a decline that, according to published medical research, does not actually occur. That gap between what the science actually says, and what influencers claim it says, is the core of the problem. It's not accidental. It's the business model. Why algorithms guarantee that such influencer claims become amplified: The functional driving force behind the influencer health misinformation problem is not primarily the individual bad actors within it — it's the platform architecture that amplifies them. Social media algorithms are engineered to maximize engagement — specifically, the clicks, shares, and watch time that generate advertising revenue. Content that triggers strong emotion performs better under these systems than content that is accurate, more complex, or less controversial. Research published in Trends in Cognitive Sciences found that social media algorithms systematically exploit human cognitive biases — particularly the tendency to weight information from socially prestigious sources and in-group members, in ways that amplify misinformation, regardless of its factual accuracy (Brady, Jackson, Lindström, and Crockett, 2023).8 An influencer who says "this molecule may modestly benefit some people under specific conditions, but we need more data" will attract a fraction of the audience of one who says "this molecule reverses aging." The algorithm does not penalize the false certainty. It rewards it. The result is a systematic selection pressure for sensationalism within health content, independent of any individual influencer's personal ethics or knowledge. This is compounded by echo chambers — algorithms that present users with content consistent with prior engagement patterns progressively narrow the informational environment, making exposure to corrective or contradictory information increasingly unlikely (Kuś, (2026).9 A consumer who watches three videos about peptide therapy will subsequently be served dozens more, each building on the prior framing, with no offsetting perspective introduced, unless specifically sought. The conflict of interest architecture: The authority that wellness influencers project depends on the appearance of independence. The commercial reality is typically the opposite. Revenue streams common to major wellness influencers include affiliate commissions on supplement sales, proprietary supplement lines, sponsorship arrangements with supplement and food companies, subscription wellness programs, direct-to-consumer telehealth clinics offering the very compounds they promote, and speaking fees from the industry events they endorse. A 2022–2023 investigation by the Washington Post and The Examination found that food, beverage, and supplement companies paid dozens of registered dietitian influencers to post promotional content, reaching millions of viewers — frequently without adequate disclosure of the commercial relationship. This is not a peripheral finding about a few rogue actors. It describes the structural relationship between the supplement industry and a significant portion of popular health influencers on major platforms. The same financial logic applies to the platform companies. They receive advertising revenue from supplement brands and wellness product companies, creating an economic interest in hosting the influencer content that drives supplement sales — independent of whether that content is accurate. There is no commercial incentive anywhere in this chain to correct misinformation that's generating revenue. What evidence-based longevity actually looks like: The genuine irony of the longevity influencer industry is that the interventions with the strongest evidence for extending healthy lifespan are largely free, widely available, and not associated with commercial products in ways that generate the margins that sustain a supplement business. Physical activity, specifically resistance training combined with aerobic conditioning, remains the single most robustly supported intervention for healthy aging, with dose-response relationships across mortality, cardiovascular disease, metabolic function, cognitive preservation, and muscle maintenance that dwarf the effect sizes of any commercially sold supplement. Sleep quality, chronic stress management, avoidance of smoking, social connection, and predominantly whole-food dietary patterns consistently outperform supplement interventions in long-term outcome data (Lim et al., 2012).10 There does exist a narrow category of supplementation that has genuine support by medical evidence. Correcting documented deficiencies in nutrients that are typically difficult to obtain at adequate levels in the diets of many individuals, especially those individuals following a restricted diet, definitely pays dividends in terms of improved long-term health. Vitamin D supplementation in deficient populations, magnesium repletion in patients with documented depletion, and creatine in older adults with sarcopenic risk (the likelihood of losing skeletal muscle mass, strength, and function) all have reasonable evidence bases. The distinction matters. Targeted repletion of a documented deficiency is not the same proposition as ingesting a biologically active compound at a supraphysiological dose (a dose, concentration, or level of a substance that's higher than what the body naturally produces or maintains) in hopes of modifying aging biology. That distinction, between correcting a known deficit and experimentation with novel compounds, is precisely the one that influencer marketing systematically ignores. Evaluating influencer claims: Consumers who engage with health content on social media are not protected by platform oversight, regulatory review, or disclosure requirements that are consistently enforced. The responsibility for evaluating claims falls largely on the individual viewing the media. Several questions reliably distinguish credible health information from marketing disguised as science:
The real cost: Beyond the direct risks of hepatotoxicity, contamination, and drug interactions, the influencer health industry inflicts a subtler and perhaps more consequential damage — it trains consumers to distrust conventional medicine while transferring that trust toward commercial actors who have optimized their presentation for exactly that distrust. The erosion of institutional health authority, driven partly by legitimate institutional failures and partly by coordinated undermining of that authority by commercial interests, ultimately harms the patients who most need reliable guidance. For patients managing chronic conditions — and MC patients are a clear example — the costs of being misled by supplement claims are not intangible. Acting on inadequately supported protocols while delaying or abandoning evidence-based management has clinical consequences. The supplement that is "worth trying" may interact with a medication, further deplete an already depleted nutrient, impose additional metabolic burden on a gut that is already compromised, or simply consume financial and cognitive resources that would be better directed elsewhere. The longevity marketplace is built on a real substrate of legitimate scientific inquiry into aging biology. That substrate is being strip-mined by a commercial ecosystem that translates preliminary findings into certainty, and uncertainty into marketable fear. Distinguishing between the two requires the same systematic skepticism that any well-constructed medical claim deserves — regardless of how silver-tongued the presenter sounds, how many papers they cite, or how many followers tell them they changed their lives. References: 1. Stocking, G., Widjaya, R., Lieb, A., Radde, K., Smith, A., and Yam, E. (2026, May 7). Trust in health and wellness influencers. Pew Research Center, Retrieved from https://www.pewresearch.org/data-labs/2026/05/07/trust-in-health-and-wellness-influencers/ 2. Global Wellness Institute. (2025). Global wellness economy monitor 2025. Global Wellness Institute, Retrieved from https://globalwellnessinstitute.org/industry-research/2025-global-wellness-economy-monitor/ 3. U.S. Food & Drug Administration. (n.d.). Information forConsumers on Using Dietry Supplements. FDA, Retrieved from https://www.fda.gov/food/dietary-supplements/information-consumers-using-dietary-supplements 4. Lin, J.K.-S., & Tujios, S.R. (2023). Hidden dangers: Herbal and dietary supplement induced hepatotoxicity. Livers, 3(4), pp 618–636. Retrieved from https://doi.org/10.3390/livers3040041 5. Editorial. (2024). Herbal and dietary supplements: Unregulated hepatotoxicity. The Lancet Gastroenterology & Hepatology, 9(11). 965. 6. Björnsson, H. K., Björnsson, E. S., Avula, B., Khan, I. A., Jonasson, J. G., Ghabril, M. . . . Navarro, V. (2020). Ashwagandha-induced liver injury: A case series from Iceland and the US Drug-Induced Liver Injury Network. Liver International, 40(4). pp 825–829. Retrieved from https://pubmed.ncbi.nlm.nih.gov/31991029/ 7. Trętowicz, M. M., Scantlebery, A. M. L., Schomakers, B. V., Eroğlu, K. D., van Weeghel, M., Spek, V., . . . Houtkooper, R. H. (2026). Human whole-blood NAD+ levels do not vary with age or lifestyle interventions. Nature Metabolism, Retrieved from https://doi.org/10.1038/s42255-026-01537-5 8. Brady, W. J., Jackson, J. C., Lindström, B., and Crockett, M. J. (2023). Algorithm-mediated social learning in online social networks. Trends in Cognitive Sciences, 27(10) pp 947–960. Retrieved from https://pubmed.ncbi.nlm.nih.gov/37543440/ 9. Kuś, J. (2026). Medical disinformation in the social media environment. Springer Nature Link, pp 223–232. Retrieved from https://link.springer.com/chapter/10.1007/978-3-032-18151-0_13 10. Lim, S. S., Vos, T., Flaxman, A. D., Danaei, G., Shibuya, K., Adair-Rohani, H., . . . Memish, Z. A. (2012). A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet, 380(9859):2224-60. Retrieved from https://pubmed.ncbi.nlm.nih.gov/23245609/
Why Official Osteoporosis Policy Has Shortchanged Magnesium, and What That Has Cost Patients For decades, the standard public health message about osteoporosis prevention has been reassuringly simple — eat more calcium, take vitamin D, get a bone density scan after menopause, and if bone loss is detected, take a prescription drug. That framework has been institutionally repeated so often that many patients and even clinicians treat it as settled biology. It's not settled. It's incomplete in ways that matter, and the gap grows harder to defend with each passing year of accumulating research. The missing piece — underemphasized in public health messaging, absent from most mainstream osteoporosis articles, and barely mentioned in clinical conversations, is magnesium. What magnesium actually does in bone: Bone is not a passive calcium reservoir. It's living tissue continuously remodeled through the coordinated activity of osteoblasts (bone-forming cells) and osteoclasts (bone-resorbing cells). Magnesium is embedded during that process at multiple levels. Approximately 50 to 60 percent of the body's total magnesium is stored in bone tissue. Beyond simple storage, magnesium is mechanistically involved in (Beale, 2023, August 15):1
Magnesium deficiency contributes to osteoporosis directly by acting on crystal formation and on bone cells, and indirectly by impairing the secretion and activity of parathyroid hormone and by promoting low-grade inflammation (Castiglion, Cazzaniga, Albisetti, Maier, 2013). 2 These are not peripheral effects. They are central to whether bone-building actually works. When magnesium is insufficient, the body pulls magnesium from bone to compensate for low intake, which can interfere with bone formation and contribute to fracture risk (Beale, 2023, August 15). The implications of the PTH connection are particularly important. Without adequate magnesium, PTH signaling becomes dysregulated. The downstream result is that calcium may not be efficiently incorporated into bone matrix — it may instead accumulate in soft tissues like arterial walls, a process associated with both cardiovascular disease and impaired bone mineralization. More calcium supplementation does not solve a problem rooted in magnesium insufficiency; it may make parts of it worse. The ratio problem nobody talks about. One of the most practically significant findings in recent bone health research concerns not just how much calcium or magnesium a person consumes, but the ratio between them. Research published in the Journal of Nutrition found that a calcium-to-magnesium ratio between 2:1 and 3:1 appears most beneficial for bone, and that anything above or below that range appears to harm bone health. There's nothing mysterious about the mechanism. Calcium and magnesium compete to be absorbed by the same mechanism in the small intestine, so consuming too much of one crowds out the other, leading to an imbalance that can weaken bones over time (Webster, 2023, October 20). 3 This finding has a direct and uncomfortable implication for current practice. Standard osteoporosis prevention advice typically emphasizes 1,000–1,200 mg of calcium per day, often through supplementation. If magnesium intake is simultaneously low — which in the United States it typically is — the calcium-to-magnesium ratio can easily reach 5:1 or 6:1, well outside the protective range. High-dose calcium supplementation without concurrent attention to magnesium may be not merely ineffective but counterproductive for skeletal health. The ratio of calcium to magnesium in the average American diet has increased from approximately 2:1 in the early twentieth century to greater than 6:1 by the year 2000. This shift has occurred alongside the widespread rise of processed foods and away from the magnesium-rich whole foods that historically comprised most diets (Tam, and Lin, 2016, April 16).4 The deficiency is real and widespread. Magnesium inadequacy in the United States is not a marginal concern. NHANES data indicate that nearly 50% of American adults consume less magnesium than the Estimated Average Requirement. The average magnesium intake in the US is approximately 216 mg/day for men and 179 mg/day for women, significantly below the Recommended Dietary Allowance of 420 mg/day for men and 320 mg/day for women (Blake, n.d.).5 And that's probably the main reason why the actual magnesium deficiency rate is much higher. The exact percentage depends on how “magnesium deficiency” is defined, because magnesium status is notoriously difficult to measure accurately. Different studies use:
A newer 2026 NHANES-based study estimated that as many as 67.8% of adults may have chronic latent magnesium deficiency using a stricter serum magnesium cutoff. Older adults appear to be at especially high risk: One study found that over 80% of older adults failed to meet recommended magnesium intake levels. That's 80% of older adults in the general population (not just MC patients) . And remember that women are much more likely to be magnesium deficient than men, so for women over 80, the odds of being magnesium deficient are extremely high. The situation is especially pronounced in the group most at risk for osteoporosis. Magnesium deficiency has been found in 84% of postmenopausal women with osteoporosis as diagnosed by low magnesium trabecular bone content (DiNicolantonio, O’Keefe, and Wilson, 2018).6 That last figure almost screams for attention, yet the standard public health response to osteoporosis remains centered on calcium. And note that several medications routinely prescribed to older adults also deplete magnesium, compounding dietary shortfalls:
Many patients taking these medications receive no corresponding guidance about magnesium monitoring or repletion, even when those same patients are simultaneously being counseled about calcium supplementation for bone health. Why isn't this information relayed to patients? The persistence of calcium-based osteoporosis messaging, despite contrary evidence, is not accidental. Several structural forces maintain it. Commercial entrenchment. The calcium supplement industry, calcium-fortified food industry, bone density scanning infrastructure, and pharmaceutical treatment of established osteoporosis represent enormous economic interests. Magnesium, whether from food or inexpensive generic supplements, generates comparatively little commercial momentum. There is no industry-funded advocacy campaign promoting spinach and pumpkin seeds the way the dairy industry promoted milk. Reductionist nutrition policy. Public health agencies tend to isolate single nutrients as primary cause-and-effect producers — calcium for bones, sodium for blood pressure, cholesterol for heart disease. This framing is administratively convenient, but biologically misleading. Bone metabolism involves magnesium, vitamin D, vitamin K2, protein, hormones, mechanical loading, inflammatory status, and kidney function working as an integrated system. No single nutrient policy captures that complexity. As one researcher involved in the calcium-to-magnesium ratio study put it, "We often research individual nutrients, but they really need to be looked at in context with one another, because that's how they're consumed in food, and how they interact with each other (Webster, 2023, October 20)." The serum magnesium testing problem. Standard serum blood tests for magnesium are notoriously unreliable indicators of total body magnesium status. Serum magnesium is automatically tightly regulated by the body, and the body will extract magnesium from bone and muscle to maintain serum levels within a normal-appearing range. A patient can have severely depleted tissue magnesium stores while testing "normal" on a routine blood panel (that includes a serum magnesium test). This makes deficiency clinically invisible until it reaches an advanced stage — and it means that physicians do not receive the laboratory feedback that would otherwise prompt intervention. A much more appropriate magnesium test to use is the RBC (red blood cell) magnesiumtest. Drug-centered healthcare. Beyond first-line pharmaceutical treatment of osteoporosis with bisphosphonates, non-pharmacological approaches with exercise, nutritional, and mineral supplements are advised — but in practice, the pharmaceutical pathway receives far more clinical training, institutional attention, and follow-up infrastructure than nutritional prevention. A doctor who prescribes a bisphosphonate after a low bone density scan is practicing within a well-defined clinical protocol. A doctor who spends time counseling a patient on magnesium-rich dietary patterns and mineral balance is largely operating outside any official treatment policy (Pickering, 2021).7 Fragmented research literature. Magnesium's role in bone health sits at the intersection of endocrinology, nephrology, orthopedics, cardiology, and nutrition. No single specialty owns the issue. A 2024 review in Frontiers in Endocrinology confirmed magnesium's essential role in bone development and mineralization and its role in the progression of osteoporosis, but this literature rarely gets integrated into unified public guidance because there's no institutional home for that body of information (Liu, Luo, Luo, Wen, Wen, and Xu, 2024).8 The Mediterranean diet contradiction: One useful example for understanding how magnesium has been systematically overlooked is the mainstream treatment of the Mediterranean diet. Public health sources routinely praise the Mediterranean dietary pattern for reducing osteoporosis risk, cardiovascular disease, inflammation, and metabolic disease. What those same sources rarely identify and explain is why the Mediterranean diet performs well on bone health outcomes. The Mediterranean diet naturally delivers high magnesium intake through its emphasis on leafy greens, legumes, nuts, seeds, whole grains, and seafood. Low consumption of ultra-processed foods means fewer magnesium-depleting dietary factors as well. In other words, a dietary pattern consistently credited with skeletal benefits is also a dietary pattern with substantially higher magnesium content than the standard Western diet. Yet official commentary attributes the bone benefits vaguely to "healthy eating patterns", while virtually never naming magnesium as a primary reason for the diet's advantages. This is not a trivial omission — it's the difference between patients receiving useful, actionable information, and patients receiving a vague recommendation they can't easily translate into a reason why they should change their eating habits. Mainstream medicine uses a reactive system to treat a preventable problem. The dominant model for osteoporosis management in the United States remains fundamentally reactive — consisting of years or decades of inadequate nutrition, followed by detectable bone loss, followed by pharmaceutical intervention after the disease is established. The drugs used at that stage, mainly bisphosphonates, denosumab, and teriparatide, can reduce fracture risk, but carry meaningful limitations, including a risk of atypical femoral fractures, osteonecrosis of the jaw, rebound bone loss after discontinuation, and incomplete restoration of bone quality and microarchitecture. They manage a disease that, in many patients, might have developed differently (or not at all) under better nutritional conditions. Controlling and maintaining magnesium homeostasis represents a helpful intervention to maintain bone integrity. And most importantly, it's an intervention available to patients years or decades before bone loss becomes clinically detectable (Castiglioni, Cazzaniga, Albisetti, and Maier, 2013). What needs to change: The required changes are not technically complicated, but they require institutions to acknowledge that a prominent omission has existed for decades. Specifically:
None of this requires abandoning calcium or vitamin D — both remain genuinely important. It requires recognizing that decades of calcium-centered messaging have not solved the osteoporosis problem, and that the science identifying why is well established and has been available for years. Among the recognized nutritional factors for osteoporosis prevention — calcium, phosphorus, vitamin D, magnesium, and fluoride — magnesium is the least reported in the literature. That ranking is a policy failure, not a reflection of magnesium's biological importance. Correcting it is straightforward. Continuing to delay that correction is a choice with measurable consequences for patient health (Chang, Yu, Ji, Wang, Yu, and Yu, 2020).9 For microscopic colitis (MC) patients, the osteoporosis risks are compounded. And not surprisingly, the bone health community largely ignores this problem. Everything described above about magnesium deficiency and osteoporosis applies to the general population. For patients with MC, the risk is substantially amplified, and this happens through mechanisms that interact and reinforce one another in ways that standard osteoporosis screening and prevention protocols are not designed to catch. MC patients commonly experience chronic, high-volume watery diarrhea. Every episode carries electrolytes out of the body, and magnesium is among the most vulnerable. Unlike sodium and potassium, magnesium is poorly conserved during persistent intestinal inflammation and rapid stool transit, meaning losses can continue for months or years before any clinical assessment of magnesium status is even considered. Simultaneously, the dietary restrictions that many MC patients develop out of necessity, such as avoiding gluten, dairy, soy, legumes, high-fiber vegetables, histamine-containing foods, and other common triggers, systematically eliminate many of the foods that would otherwise supply the most dietary magnesium. Seeds, legumes, leafy greens, nuts, and whole grains are all magnesium-dense; they are also foods that a significant proportion of MC patients cannot tolerate without triggering symptoms. The result is a patient simultaneously losing magnesium through the gut while being unable to replace it through diet. The overlap between MC and gluten sensitivity or celiac disease adds another layer. Gluten-related enteropathy damages the absorptive surface of the small intestine, impairing uptake of magnesium, calcium, vitamin D, zinc, and protein — the full complement of nutrients that bone metabolism depends on. For patients who go undiagnosed or inadequately managed for years, this malabsorption may operate quietly in the background long before bone density loss becomes measurable on a scan. Corticosteroid treatment creates yet another compounding variable. Budesonide, the most commonly prescribed medication for MC, is generally described as having fewer systemic effects than prednisone, but prolonged use is not without skeletal consequence. Long-term corticosteroid exposure can reduce bone formation, impair calcium balance, and contribute to muscle wasting — which itself elevates fracture risk through reduced musculoskeletal support and increased fall susceptibility. Patients who cycle through repeated courses of budesonide over years, as many MC patients do, accumulate this risk without it appearing prominently in any single clinical encounter. What makes this particularly concerning is the timeline. Standard osteoporosis detection relies on bone density scanning, which captures damage that has already occurred. MC-related skeletal deterioration (due to chronic magnesium depletion, malabsorption, inflammation, restricted diet, and intermittent corticosteroid use) may begin accumulating years or even decades before a bone density scan crosses the diagnostic threshold for osteoporosis. By the time the diagnosis is made, the window for prevention has largely closed, and management shifts to pharmaceutical treatment of an established disease. The conventional clinical response to this situation — advising calcium supplementation, and perhaps a bisphosphonate after bone loss is detected — misses the upstream biology. As the earlier sections of this article point out, calcium cannot be properly regulated, transported, or incorporated into bone without adequate magnesium. For MC patients, who face both accelerated magnesium losses and impaired magnesium absorption, calcium-based prevention advice is particularly inadequate. A more rational approach starts with restoring and maintaining magnesium sufficiency, optimizing vitamin D status, preserving protein intake, controlling chronic inflammation, and minimizing steroid exposure; all the while recognizing that dietary restrictions may require supplementation strategies tailored to what individual patients can actually tolerate and absorb. Osteoporosis in MC is not simply an age-related complication that happens to coincide with a bowel condition. For many patients, it's a direct, long-term consequence of the disease itself, due to years of electrolyte losses, malabsorption, restricted diet, and chronic inflammatory condition, resulting in a healthcare environment that evaluates these problems as separate clinical issues, rather than recognizing them as a unified, manageable risk. Consider the tradeoffs if drugs are selected for treating osteoporosis. The reactive model described throughout this article — inadequate nutrition for decades, followed by pharmaceutical treatment after bone loss is established — depends on drugs that are routinely described to patients in reassuringly simple terms. "This will strengthen your bones" is the kind of shorthand that gets used in clinical encounters. The biology is considerably more complicated, and patients who understand it are better positioned to make genuinely informed decisions. Bisphosphonates: What Denser Bones on a Scan Actually Means. Bisphosphonates, sold under names including Fosamax, Actonel, Boniva, and Reclast are the most widely prescribed drugs for osteoporosis. They work by suppressing osteoclast activity, the cellular process that removes and remodels old bone. Less bone removal means that mineralized tissue accumulates, which typically shows up as improved bone mineral density on DEXA scans. But that mechanism contains a biological paradox that's rarely explained to patients. Prolonged bisphosphonate use leads to inhibition of bone resorption and causes osteoclast apoptosis (programed cell death), resulting in accumulation of microdamage and reduced bone remodeling. Bone is not a static mineral deposit — it's living tissue that requires continuous remodeling to clear accumulated microdamage, and maintain structural integrity. When that remodeling is suppressed long enough, bone may become measurably denser, but it does so at the expense of becoming more brittle. And it does so in ways that a DEXA scan cannot detect (Caldaci et al., 2025).10 In other words, it “fools“ the test. That concern has a clinical aspect. A concerning paradox has emerged in which long-term bisphosphonate use, while effective at reducing typical osteoporotic fractures, is associated with a rare but serious complication known as atypical femoral fractures, which are unusual breaks that occur in the shaft of the femur and differ significantly from common osteoporotic fractures in terms of location, appearance, and mechanism (Mohamed, Fuad, Abdelazim, Elasad, and Bhamidipati, 2025).11 The risk is not unchanging across time. The risk of an atypical fracture increases with longer duration of bisphosphonate use, with the hazard ratio increasing substantially when compared with less than 3 months of use. The absolute risk of atypical femoral fracture rises to approximately 100 per 100,000 patient-years after five to eight years of continuous therapy. At that point, cessation of bisphosphonates can result in a 70% reduction in the risk of developing atypical femoral fracture (Black et al., 2020).12 Beyond atypical fractures, bisphosphonates carry additional known risks, including osteonecrosis of the jaw, impaired bone healing after dental procedures or surgery, and gastrointestinal complications. For patients already dealing with gastrointestinal disease (as all MC patients are) that last risk deserves particular attention. None of this means bisphosphonates are never useful. In patients with severe osteoporosis and high near-term fracture risk, their ability to reduce vertebral fractures is real and documented. The relevant clinical question is whether a patient's situation warrants accepting those tradeoffs — a question that requires honest disclosure of what those tradeoffs actually are. Denosumab (Prolia) is a drug that can't simply be stopped. Denosumab, marketed as Prolia, works differently from bisphosphonates. It's a monoclonal antibody that blocks RANKL, a protein required for osteoclast formation, thereby suppressing bone resorption. It's effective at reducing fractures during treatment. The problem emerges when a treatment ends. Denosumab rebound-associated fractures occur in approximately 1 out of 14 patients who discontinue denosumab therapy without receiving antiresorptive therapy. The fractures occur due to excessive bone resorption after missed or delayed denosumab doses, and can be multiple and seriously alter quality of life (Jain, 2024).13 The mechanism is straightforward, but rarely communicated to patients at the time treatment begins, because denosumab suppresses osteoclast formation rather than binding to bone the way bisphosphonates do, its effects are fully reversible when the drug clears the system. Approximately 6 months after the last denosumab injection, bone turnover markers increase rapidly, exceeding baseline values and remaining elevated before returning to baseline approximately 30 months after the last injection. Bone mineral density gains are lost, sometimes incompletely, sometimes falling even below pretreatment baseline values (Burckhardt, Faouzi, Buclin, Lamy, and The Swiss Denosumab Study Group, 2021).14 The adjusted odds ratio for multiple vertebral fractures after denosumab discontinuation was highest between 3 and 9 months after stopping the drug, and the risk increased substantially with longer duration of prior treatment — with 5- to 11-times increased fracture risk when discontinuing after 1–5 years of use (Martín-Pérez, Sánchez-Delgado, García-Poza, López-Álvarez, and Martín-Merino, 2025).15 What this means practically is that starting denosumab is, in most cases, a long-term commitment. Stopping without careful transition to another antiresorptive agent can leave the patient in a worse fracture-risk position than before treatment began. That consequence needs to be part of the informed consent conversation — and frequently it's not. Anabolic drugs are more targeted, but still not without tradeoffs. romosozumab (Evenity), work by stimulating bone formation rather than simply suppressing resorption, making them conceptually more aligned with how healthy bone metabolism functions. They can produce more meaningful improvements in bone architecture than antiresorptive drugs in some patients. Their limitations and risks are different but equally worth understanding. Potential serious side effects of anabolic agents include risk of malignancies in teriparatide and abaloparatide users, and cardiovascular events in romosozumab users. Teriparatide and abaloparatide carry an FDA boxed warning restricting lifetime cumulative use to no more than two years, based on osteosarcoma findings in rodent studies, (although the direct human risk remains debated). Romosozumab received initial regulatory scrutiny over cardiovascular safety signals identified in phase III trials, and concerns about increased cardiovascular adverse events related to romosozumab persist, with further investigation considered essential to understand whether it is involved in the development of cardiovascular events (di Filippo and Rosen, 2024).16 All anabolic agents also share a structural limitation — their bone-building effects diminish over time, treatment durations are capped, and the gains made during treatment require maintenance with antiresorptive therapy afterward to prevent being lost. The drug sequence matters, and the long-term management remains complex. The larger problem these drugs cannot fix. Every current osteoporosis drug involves biological tradeoffs. Some can meaningfully reduce fracture risk in the right patient at the right time. None of them addresses why the bone was lost in the first place, and none of them restores the bone quality that decades of adequate nutrition, mechanical loading, and controlled inflammation would have preserved. For MC patients specifically, several of these tradeoffs carry amplified significance. The gastrointestinal side effects of oral bisphosphonates pose additional challenges for patients whose gut is already compromised. The rebound fracture risk of denosumab is particularly concerning for patients whose underlying disease, dietary restrictions, and nutrient depletion make transitional management more difficult. And the cardiovascular concerns with romosozumab are relevant to any patient population facing chronic inflammation, which is associated with elevated cardiovascular risk independent of skeletal disease. The argument is not that these drugs should be refused when they are genuinely indicated. It's that pharmaceutical treatment of established osteoporosis in MC patients (or in anyone) is a considerably more complicated proposition than it's typically presented to be. The bottom line: Clearly, the resources invested in managing late-stage bone disease would be far better replaced by protective measures applied upstream to prevent the bone damage that makes these drugs necessary. In most cases, a few dollars invested in regular magnesium supplements early on could easily prevent the need for later drug treatments costing many thousands of dollars, and carrying huge health risks. Yet the calcium fixation problem continues, and patients continue to suffer needlessly as those who decide medical policy continue to sit on their thumbs and watch osteoporosis develop ad nauseum. References: 1. Beale, C. (2023, August 15). Magnesium and Bone Health. Wellen, Retrieved from https://www.getwellen.com/well-guide/magnesium-and-bone-health 2. Castiglioni, S., Cazzaniga, A., Albisetti, W., and Maier, J. A. M., (2013). Magnesium and Osteoporosis: Current State of Knowledge and Future Research Directions. Nutrients, 5(8). pp 3022–3033. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC3775240/ 3. Webster, K. (2023, October 20). Doctoral Candidate Says Calcium and Magnesium Work Better Together. University of Massachusetts at Lowell, Retrieved from https://www.uml.edu/news/stories/2023/research-osteoporosis.aspx 4. Tam, Y. K. and Lin, G. (2016, April 16). Formulas comprising highly soluble elements and vitamins for the prevention and amelioration of osteoporosis. United states Patent, Retrieved from https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9308222 5. Blake, S. (n.d.). Magnesium Deficiency Statistics. Zipdo, Retrieved from https://zipdo.co/magnesium-deficiency-statistics/ 6. DiNicolantonio, J. J., O’Keefe, and J. H., Wilson, W. (2018). Subclinical magnesium deficiency: a principal driver of cardiovascular disease and a public health crisis. Open heart, 5(1). e000668. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC5786912/ 7. Pickering, M.-E. (2021). Cross-Talks between the Cardiovascular Disease-Sarcopenia-Osteoporosis Triad and Magnesium in Humans. International Journal of Molecular Sciences, 22(16). 9102. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC8396464/ 8. Liu, L., Luo, P., Luo, P., Wen, P., Wen, P., and Xu, P. (2024). The role of magnesium in the pathogenesis of osteoporosis. Frontiers in Endocrinology, 15. 1406248. Retrieved from https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2024.1406248/full 9. Chang, J., Yu, D., Ji, J., Wang, N., Yu, S., and Yu, B. (2020). The Association Between the Concentration of Serum Magnesium and Postmenopausal Osteoporosis. Frontiers in Medicine, 7. 381. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC7417435/ 10. Chang, J., Yu, D., Ji, J., Wang, N., Yu, S., and Yu, B. (2020). The Association Between the Concentration of Serum Magnesium and Postmenopausal Osteoporosis. Frontiers in Medicine, 7. 381. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC7417435/ 11. Mohamed, A., Fuad, U., Abdelazim, M., Elasad, A., Bhamidipati, P. (2025). Bisphosphonate-Related Atypical Femoral Fractures: A Comprehensive Review. Cureus. 17(11). e96208. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC12681184/ 12. Black, D. M., Geiger, E, J., Eastell, R. E., Vittinghoff, E., Li, B. H., Ryan, D. S., . . . Adams, A. L. (2020). Atypical Femur Fracture Risk versus Fragility Fracture Prevention with Bisphosphonates. The New England Journal of Medicine, 383(8). pp 743–753 Retrieved from https://www.nejm.org/doi/full/10.1056/NEJMoa19165 13. Jain, S. (2024). Prevention and Management of Denosumab Discontinuation Rebound Fractures. Endocrinology and Metabolism Clinics of North America, 3(4). pp 559-583. Retrieved from https://pubmed.ncbi.nlm.nih.gov/39448137/ 14. Burckhardt, P., Faouzi, M., Buclin, T., Lamy, O., and The Swiss Denosumab Study Group. (2021). Fractures After Denosumab Discontinuation: A Retrospective Study of 797 Cases. Journal of Bone and Mineral Research, 6(9). pp1717–1728. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC 15. Martín-Pérez, M., Sánchez-Delgado, B., García-Poza, P., López-Álvarez, S., and Martín-Merino, E. (2025). Multiple vertebral fractures after antiosteoporotic medications discontinuation: A comparative study to evaluate the potential rebound effect of denosumab. Bone (on Science Direct), 190. 117325. Retrieved from https://www.sciencedirect.com/science/art 16.di Filippo, L., and Rosen, C. J., (2024). Latest on Anabolic Agents for Osteoporosis Treatment. Endocrinology and Metabolism Clinics of North America, 3(4). pp 513–523. Retrieved from https://pubmed.ncbi.nlm.nih.gov/39448133/
Official medical guidelines often contain worrisome problems. One of those, for example, is the disparity between minimal vitamin D threshold levels set by official guidelines, and the levels that epidemiological data suggest are optimal for much broader disease prevention. This disconnect is real and has been the subject of growing debate among researchers, clinicians, and patient advocates. Does this risky gap exists because of unintended oversight, or a more systemic incentive problem. Official medical vitamin D guidelines reflect minimal standards.
These guidelines typically set the sufficiency cutoff around 20–30 ng/mL (50–75 nmol/L). But these levels are based on outdated endpoints and ignore the non-skeletal roles of vitamin D, such as:
By contrast, epidemiological studies routinely associate 40–60 ng/mL (100–150 nmol/L) with lower risks of:
Fear of toxicity has led to overly conservative guidelines. Regulators remain cautious because:
However, numerous studies show that levels up to 100 ng/mL are safe and that daily supplementation of 2000–5000 IU is rarely associated with harm, especially when magnesium and vitamin K2 intake are adequate. Yet, the official upper intake limit remains at 4000 IU/day, a conservative figure not supported by more recent safety data. Guideline selecting committees reflect medical conservatism and risk aversion. Organizations such as the Endocrine Society tend to prioritize:
This conservative approach leads to an unrealistic "wait for perfect proof" mentality, despite real-world, population-level correlations suggesting otherwise. Pharmaceutical and insurance incentives tend to disincentive prevention. While it may be unfair to claim the system is intentionally keeping people deficient to drive healthcare profits, structural incentives do create passive disincentives for prevention:
In this sense, the system, as designed, doesn’t reward optimal public health outcomes—it rewards sick care. Guidelines recommend inadequate testing and diagnostic practices. Routine vitamin D testing is discouraged for the general population under current guidelines, despite:
Note that this is similar to the neglect seen with magnesium testing, where reliance on inaccurate serum levels prevents effective diagnosis and intervention. The message sent to the public is confusing and contradictory. Medical authorities often:
This has led to public confusion, under-supplementation, and persistent population-level deficiency—despite decades of emerging research. So do the guidelines encourage sickness rather than disease prevention? There's no clear evidence of any coordinated conspiracy, of course, but:
all contribute to the persistence of low thresholds that serve institutional interests more than patient well-being. In that light, it's fair to argue the system is not designed to promote optimal health. It manages disease reactively rather than preventing it proactively. Vitamin D levels are especially important for IBD patients. Research shows that vitamin D deficiency affects up to 100% of Crohn's disease patients and 45% of those with ulcerative colitis (Johnson, 2025, May 20).1 The deficiency is not merely a result of disease activity — it likely contributes to its onset. Mechanistically, low vitamin D leads to:
Low vitamin D correlates with increased disease activity, more frequent surgeries, higher relapse rates, and poor treatment responses. A 2023 Cochrane review even found reduced relapse rates in patients supplementing with vitamin D, although evidence quality limited definitive conclusions. Another study followed 5,474 IBD patients for 13 years and found that those with adequate vitamin D levels had significantly reduced bowel resection risks — by 34% in IBD overall and 46% in ulcerative colitis (Dan et al., 2024).2 The takeaway: Despite self-serving and often confusing official vitamin D guidelines:
Additional evidence of the safety of higher doses: The Calgary vitamin D study: was a three year, double-blind, random controlled study (RCT) involving adults aged 55–70, and compared daily doses of either 4000 IU or 10,000 IU of vitamin D (Burt et al., 2019).3 The findings showed that both 4000 and 10,000 IU per day were well-tolerated. Bone density was generally unaffected, but was slightly decreased at the highest does, suggest the safety, but no skeletal benefit at high levels in already sufficient adults. The VIDAMS study (multiple sclerosis): compared 5000 IU per day versus 600 IU per day in relapsing remitting multiple sclerosis patients (Cassard et al., 2023).4 The findings showed that the higher dose yielded fewer active MRI lesions, indicating potential benefit beyond bone health. A systematic review and meta-analysis: based on 32 reviews of clinical trials involving 8400 children who received high-dose vitamin D treatments ranging from 1200 to 10,000 IU per day, and bolus doses ranging from 30,000 IU per week to a single dose of 600,000 IU, found that no increased risk of serious adverse events was associated with high-dose vitamin D treatments (Brustad et al., 2022).5 References: 1. Johnson, D. A. (2025, May 20). The Overlooked Link Between Vitamin D and GI Health. Medscape, Retrieved from https://www.medscape.com/viewarticle/overlooked-link-between-vitamin-d-and-gi-health-2025a1000bki?ecd=mkm_ret_250706_mscpmrk_gastro_Lower-GI_etid7539875&uac=95382HN&impID=7539875 2. Dan, L., Wang, S., Chen, X., Sun, Y. Fu, T., Deng, M., . . . Wang, X. (2024). Circulating 25-hydroxyvitamin D concentration can predict bowel resection risk among individuals with inflammatory bowel disease in a longitudinal cohort with 13 years of follow-up. International Journal of Surgery, [Published online]. Retrieved from https://journals.lww.com/international-journal-of-surgery/abstract/9900/circulating_25_hydroxyvitamin_d_concentration_can.1249.aspx 3. Burt, L. A., Billington, E. O., Rose, M. S., Raymond, D. A., Hanley, D. A., and Boyd, S. K. (2019). Effect of High-Dose Vitamin D Supplementation on Volumetric Bone Density and Bone Strength: A Randomized Clinical Trial. JAMA, 322(8), pp 736–745, Retrieved from https://pubmed.ncbi.nlm.nih.gov/31454046/ 4. Cassard, S. D., Fitzgerald, K. C., Qian, P., Emrich, S. A., Azevedo, C. J., Goodman, A.D., . . . Mowry, E. M. (2023) High-dose vitamin D3 supplementation in relapsing-remitting multiple sclerosis: a randomised clinical trial. EClinicalMedicine, 13;59,101957. Retrieved from https://pubmed.ncbi.nlm.nih.gov/37125397/ 5. Brustad, N., Yousef, S., Stokholm, J., Bønnelykke, K., Bisgaard, H., and Chawes, B. L. (2022). Safety of High-Dose Vitamin D Supplementation Among Children Aged 0 to 6 Years: A Systematic Review and Meta-analysis. JAMA Network Open, 5(4). e227410 Retrieved from https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2791031
|
AuthorWayne Persky Archives
November 2026
Categories |
RSS Feed